Clinical Trials Browser

Phase 2 × Bronchiolitis Obliterans Syndrome × 1 year × Clear all

NCT04710576 2026-03-16

AGAVE-201

Phase 2 Active not recruiting

241 enrolled 11 charts 1 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT06271616 2025-12-26

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Phase 2 Recruiting

Bronchiolitis Obliterans Syndrome

NCT03774082 2025-12-11

REACH 5

Phase 2 Completed

46 enrolled 21 charts

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Lymphoma, Follicular

NCT05951777 2025-09-29

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Phase 2 Recruiting

Brain Injuries, Traumatic, Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Trauma, Nervous System, Intracranial Hemorrhages

NCT04795427 2025-04-18

Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors

Phase 2 Completed

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive